Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 301–400 of 3,116
Gunnarsson, S., Vito, O., & Unwin, R. J. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00499.2025 · Cited by 52
Machine learning in cardiovascular risk assessment: Towards a precision medicine approach
Wang, Y., Aivalioti, E., Stamatelopoulos, K., Zervas, G., Mortensen, M. B., Zeller, M., Liberale, L., Vece, D. D., Schweiger, V., Camici, G. G., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70017 · Cited by 50
Karakasis, P., Patoulias, D., Kassimis, G., Koufakis, T., Klisic, A. N., Doumas, M. N., Fragakis, N., & Rizzo, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128304097240529053538 · Cited by 34
Heffernan, A., Duplančić, D., Kumrić, M., Kurir, T. T., & Božić, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063243 · Cited by 39
Joshi, G. P., LaMasters, T. L., & Kindel, T. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005231 · Cited by 32
Koychev, I. G., Reid, G., Nguyen, M., Mentz, R. J., Joyce, D. W., Shah, S. H., & Holman, R. R. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01573-x · Cited by 39
Geroscience: A Translational Review
Kritchevsky, S. B., & Cummings, S. R. (2025) · JAMA · doi:10.1001/jama.2025.11289 · Cited by 52
Chen, M., Guo, J., Shangguan, Y., Sun, Z., He, X., Tu, Q., & Yan, Q. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02921-3 · Cited by 49
Alexiadou, K., Hartley, A., Tan, T. M.-M., & Khamis, R. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.03.003 · Cited by 31
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 46
Wang, W., Davis, P. B., Qi, X., Gurney, M. E., Perry, G. L., Volkow, N. D., Kaelber, D. C., & Xu, R. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251351329 · Cited by 38
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
“…signi fi cantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease (Lincoff et al., 2023; Marso et al., 2016a).”
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies
Haberman, R. H., Ogdie, A., Merola, J. F., Scher, J. U., & Eder, L. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01326-6 · Cited by 51
“Furthermore, the extensive cardiovascular benefits reported with GLP-1-based therapies are not observed with the other approved weight loss drugs 223 ; however, orlistat has shown mild cardiovascular benefits 224 , and phentermine–topiramate and naltrexone–bupropion have shown mixed results…”
Cohen, O., Kundel, V., Barbé, F., Peker, Y., McEvoy, R. D., Sánchez‐de‐la‐Torre, M., Gottlieb, D. J., Bradley, T. D., Suárez‐Fariñas, M., Zinchuk, A. V., et al. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202409-981st · Cited by 42
Singh, S. T., Garg, A., Tantry, U. S., Bliden, K. P., Gurbel, P. A., & Gulati, M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102403 · Cited by 38
Lin, K., Ai, W., Zhai, C., Zhao, Y., Hu, H., Huang, D., Zhai, Q., Yan, Y., & Ge, J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17327 · Cited by 39
Chowdhary, A., Thirunavukarasu, S., Joseph, T., Jex, N., Kotha, S., Giannoudi, M., Procter, H., Cash, L., Akkaya, S., Broadbent, D. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.064 · Cited by 38
Alkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
Gao, A., Peng, B., Gao, Y., Yang, Z., Li, Z., Guo, T., Qiu, H., & Gao, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01687-8 · Cited by 43
Obesity and Cardiovascular Disease: A New Dawn
Sattar, N. A., Neeland, I. J., & McGuire, D. K. (2024) · Circulation · doi:10.1161/circulationaha.123.065485 · Cited by 31
Rivera Gutierrez, R., Tama, E., Bechenati, D., Castañeda Hernandez, R., Bennett, P. K., McNally, A. W., Fansa, S., Anazco, D., Acosta, A., & Hurtado Andrade, M. D. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.07.006 · Cited by 31
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
Nakhla, M., Nair, A. V., Balani, P., Ujjawal, A., Kumar, P. A., Dasari, M., Yukselen, Z., Bansal, K., Ganatra, S., & Dani, S. S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07613-w · Cited by 49
Jensen, T. L., Brønden, A., Karstoft, K., Sonne, D. P., & Christensen, M. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s419304 · Cited by 36
Dani, S. S., Makwana, B., Khadke, S., Kumar, A., Jhund, P., Nasir, K., Sattar, N., Al-Kindi, S., Fonarow, G., Butler, J., et al. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2025.101740 · Cited by 30
Heitmann, B. L. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00611-5 · Cited by 30
GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Stefater‐Richards, M. A., Jhe, G., & Zhang, Y. J. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068119 · Cited by 42
Impact of Visceral and Hepatic Fat on Cardiometabolic Health
Khawaja, T., Nied, M., Wilgor, A., & Neeland, I. J. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02127-1 · Cited by 49
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 41
A Comprehensive Review: Unraveling the Role of Inflammation in the Etiology of Heart Failure
Pepine, D., Șerban, A. M., Capraș, R.-D., Cismaru, C. M., & Filip, G. A. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10519-w · Cited by 49
Cleto, A. S., Schirlo, J. M., Beltrame, M. L., Gomes, V. H. O., Acras, I. H., Neiverth, G. S., da Silva, B. B., Juliatto, B. M. S., Machozeki, J., & Martins, C. M. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01646-9 · Cited by 37
Semaglutide-associated kidney injury
Begum, F., Chang, K., Kapoor, K., Vij, R. S., Phadke, G. M., Hiser, W. M., Wanchoo, R., Sharma, P., Sutaria, N., & Jhaveri, K. D. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae250 · Cited by 38
The Ethics of Ozempic and Wegovy
Ryan, N., & Savulescu, J. (2025) · Journal of Medical Ethics · doi:10.1136/jme-2024-110374 · Cited by 81
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 39
Stenberg, E., Ottosson, J., Cao, Y., Sundbom, M., & Näslund, E. B. (2024) · British journal of surgery · doi:10.1093/bjs/znae221 · Cited by 37
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Arsenault, B. J., Carpentier, A. C., Poirier, P., & Després, J. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117546 · Cited by 38
Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon
Byrne, C. D., Targher, G., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2023-330596 · Cited by 34
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
“…SELECT RCT, which included 17,604 patients with pre-existing CVD and overweight or obesity but without diabetes, subcutaneous semaglutide (2.4 mg once weekly) reduced the rate of the primary composite end point of death from cardiovascular causes, MI or stroke by 20% compared with placebo 355,356 .”
InfluentialEl-Solh, A., Gould, E., Aibangbee, K. E., Jimerson, T., & Hartling, R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2437525 · Cited by 34
Astrup, A. V. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01460-6 · Cited by 42
The effect of obesity pharmacotherapy on body composition, including muscle mass
Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01533-3 · Cited by 28
“Recently, the SELECT trial demonstrated an impressive decline of cardiovascular risk by 20% in individuals without diabetes [40].”
Somani, S. S., Jain, S. S., Sarraju, A., Sandhu, A. T., Hernandez‐Boussard, T., & Rodríguez, F. (2024) · Communications Medicine · doi:10.1038/s43856-024-00566-z · Cited by 36
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 50
Kramer, C. K., Retnakaran, M., & Viana, L. V. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae176 · Cited by 33
Jarade, C., Zolotarova, T., Moiz, A., & Eisenberg, M. J. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102789 · Cited by 32
Lee, V. Y., Houston, L., Perkovic, A., Barraclough, J., Sweeting, A., Yu, J., Fletcher, R. A., & Arnott, C. G. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.11.022 · Cited by 32
Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Packer, M., Zile, M. R., Desai, A. S., Shah, A. M., Čikeš, M., Merkely, B. P., Gori, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3304 · Cited by 30
Chiang, C., Song, J., Chi, K., Chang, Y.-C., Xanthavanij, N., Chang, Y., Hsia, Y. P., Chiang, C.-H., Ghamari, A., Reynolds, K. L., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115170 · Cited by 35
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT)
Verma, S., Colhoun, H. M., Dicker, D., Hovingh, G. K., Kahn, S. E., Kautzky‐Willer, A., Lingvay, I., Plutzky, J., Rasmussen, S., Rathor, N., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.022 · Cited by 29
Self-citationDavies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 61
Self-citationTreating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Chen, A. S., & Batsis, J. A. (2025) · Diabetes · doi:10.2337/dbi25-0004 · Cited by 32
Cardioprotective Effects of Semaglutide on Isolated Human Ventricular Myocardium
Krammer, T., Baier, M. J., Hegner, P., Zschiedrich, T., Lukas, D., Wolf, M., Phu, C. L., Lutz, V., Evert, K., Kozakov, K., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3644 · Cited by 33
The prevention and management of chronic kidney disease among patients with metabolic syndrome
Zhu, D., Judge, P. K., Wanner, C., Haynes, R., & Herrington, W. G. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.021 · Cited by 37
Moiz, A., Zolotarova, T., Filion, K. B., & Eisenberg, M. J. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpaf205 · Cited by 26
Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02781-x · Cited by 26
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Inflammatory Mechanisms in Acute Coronary Syndromes: From Pathophysiology to Therapeutic Targets
Brie, D. M., Mornoş, C., Adam, O., Tîrziu, A., Popescu, R., & Brie, A. D. (2025) · Cells · doi:10.3390/cells15010072 · Cited by 34
“The SELECT trial, involving over 17,000 high-risk cardiovascular patients without diabetes, found semaglutide reduced high-sensitivity CRP by 12–20% within 4–8 weeks of treatment, even before significant weight loss [220].”
Villaschi, A., Ferrante, G., Cannata, F., Pini, D., Pagnesi, M., Corrada, E., Reimers, B., Mehran, R., Federici, M., Savarese, G., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02362-6 · Cited by 31
Levidy, M. F., Vatsia, S. K., Gohel, N., Rowe, N. D., Kirchner, G. J., DeMedal, S., & Mason, M. (2025) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-24-01284 · Cited by 30
Yin, Y., Zhang, M., Cao, Q., Lin, L., Lu, J., Bi, Y., & Chen, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70082 · Cited by 35
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
“Expanding the scope of these findings, the SELECT trial, published in 2023, evaluated the cardiovascular efficacy of semaglutide 2.4 mg in individuals with overweight or obesity and history of ASCVD but without T2D [49].”
InfluentialWang, T., Ding, J., Cheng, X., Yang, Q., & Hu, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1396656 · Cited by 34
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 57
Factors Associated With Semaglutide Initiation Among Adults With Obesity
Podolsky, M. I., Raquib, R., Shafer, P. R., Hempstead, K., Ellis, R. P., & Stokes, A. C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.55222 · Cited by 26
Añazco, D., & Acosta, A. J. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01599-z · Cited by 43
New approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26
“A. Filtz et al. [95].”
Cheng, J., Solomon, T., Estee, M. M., Cicuttini, F., & Lim, Y. Z. (2025) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2025.100567 · Cited by 33
Obesity medications: A narrative review of current and emerging agents
Qi, Q., Cox, A., McNeil, S. E., & Sumithran, P. (2024) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2024.100472 · Cited by 41
Rroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 34
KHADKE, S., KUMAR, A., BHATTI, A., DANI, S. S., AL-KINDI, S., NASIR, K., VIRANI, S. S., UPADHYAY, J., GARCIA-BANIGAN, D. C., ABRAHAM, S., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.10.448 · Cited by 25
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Mollan, S. P. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.2514 · Cited by 27
Petta, S., Kim, K., Targher, G., Romeo, S., Sookoian, S. C., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70407 · Cited by 36
“Interestingly, the cardiovascular benefits of GLP-1RAs do not seem to be limited only to patients with T2D [47, 48].”
InfluentialPerone, F., Spadafora, L., Pratesi, A., Nicolaio, G., Pala, B., Franco, G., Ruzzolini, M., & Ambrosetti, M. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200331 · Cited by 47
Heo, K., Phan, L. P., Le, N. T. T., & Jin, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01542-4 · Cited by 35
Chiang, C., Song, J., Chang, Y., Osataphan, S. A., Lee, Y.-C., Chang, K.-Y., Chi, K.-Y., Chiang, C., Dua, A., Lake, L. L., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015871 · Cited by 28
Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T. (2026) · Nature Communications · doi:10.1038/s41467-025-67701-9 · Cited by 29
“Moreover, a large-scale randomized controlled trial (RCTs) involving more than 17,000 individuals with obesity and car-diovasculardiseasedemonstratedthatsemaglutidereducedtheriskof cardiovasculardeath,myocardialinfarction(MI),andstrokecompared to the placebo 9 .”
Aroda, V. R., Jørgensen, N. B., Kumar, B., Lingvay, I., Laulund, A. S., Buse, J. B., & trial investigators (2025) · Diabetes Care · doi:10.2337/dc24-2425 · Cited by 25
Self-citationTanaka, A., & Node, K. (2024) · Hypertension Research · doi:10.1038/s41440-024-01737-0 · Cited by 29
The association between weight loss medications and cardiovascular complications
Başer, O., Samayoa, G., Rodchenko, K., Isenman, L., Baser, E., & Yapar, N. (2024) · Obesity · doi:10.1002/oby.24037 · Cited by 32
Visceral Adiposity and Cardiometabolic Risk: Clinical Insights and Assessment
Shetty, S., Suvarna, R., Bhattacharya, S., & Seetharaman, K. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000984 · Cited by 40
Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 34
Ahmad, A., & Sabbour, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02192-4 · Cited by 25
Rethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review
Tuccinardi, D., Watanabe, M., Masi, D., Monte, L., Meffe, L. B., Cavallari, I., Nusca, A., Maddaloni, E., Gnessi, L., Napoli, N., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae171 · Cited by 32
Tobaiqy, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00629-x · Cited by 25
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
The real‐life experiences of people living with overweight and obesity: A psychosocial perspective
Flint, S. W., Vázquez‐Velázquez, V., Brocq, S. L., & Brown, A. C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16255 · Cited by 35
The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis
Sasaki, T., Giang, S. M.-L., Wu, J., Yokoo, T., Gallagher, M., Bellomo, R., & Wang, Y. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf193 · Cited by 41
Multimorbidity in patients with atrial fibrillation
Lobeek, M., Middeldorp, M. E., Gelder, I. C. V., & Rienstra, M. (2024) · Open Heart · doi:10.1136/openhrt-2024-002641 · Cited by 28
Battistoni, A., Piras, L., Tartaglia, N., Carrano, F. M., Vitis, C. D., & Barbato, E. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1669685 · Cited by 49
Malnutrition in patients with obesity: An overview perspective
Cristancho, C., Mogensen, K. M., & Robinson, M. K. (2024) · Nutrition in Clinical Practice · doi:10.1002/ncp.11228 · Cited by 31
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
“In the SELECT trial, 2.4 mg semaglutide weekly or placebo was administered to over 16,000 patients with overweight/obesity and established cardiovascular disease (85).”
InfluentialDash, S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15829 · Cited by 24
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
MacIsaac, R. J., Trevella, P., & Ekinci, E. I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13609 · Cited by 31
Wong, H. J., Toh, K. Z. X., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y., Zhou, X., Yang, Q., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003903 · Cited by 29
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Ali, M. M., Parveen, S., Williams, V. R., Dons, R. F., & Uwaifo, G. I. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100341 · Cited by 41
Kadowaki, T., Heftdal, L. D., Ko, H., Overvad, M., Shimomura, I., Thamattoor, U. K., Kim, K. K., OASIS 2 Investigators, Kunishige, H., Okude, J., et al. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.3599 · Cited by 34
Bonaca, M. P., Catarig, A., Hansen, Y., Houlind, K. C., Ramesh, C. K., Ludvik, B. H., Nordanstig, J., Rasouli, N., Sourij, H., & Verma, S. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae071 · Cited by 26
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
